Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer.
We have two small molecule anticancer compounds under evaluation in human clinical trials. Our potential product, laromustine (Cloretazine®, VNP40101M) is being evaluated for the treatment of acute myelogenous leukemia (AML) in a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition, three clinical trials of laromustine (Cloretazine®, VNP40101M) are underway in: (i) elderly AML and myelodysplastic syndromes in combination with cytarabine; (ii) brain tumors in combination with temozolomide; and (iii) advanced hematologic malignancies in combination with hematopoietic cell transplantation. Our potential product, Triapine® is under evaluation in clinical studies sponsored by the National Cancer Institute.
We appreciate your interest in our company. Our management and staff are dedicated to one purpose: developing therapeutic drugs for cancer.
Follow the links to learn more about our company and our people, to read our latest news, or to contact us.